Long Assets On Path To Creating Significant Value, Shorting Remains Very ChallengingSeeking Alpha • 08/06/24
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of ImmunologyBusiness Wire • 06/03/24
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston SummitBusiness Wire • 05/15/24
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) BiotherapeuticsAccesswire • 04/15/24
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsBusiness Wire • 03/20/24
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?Zacks Investment Research • 02/28/24
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics ConferenceBusiness Wire • 12/14/23
OmniAb, Inc. (OABI) Research and Technology Virtual Event and Q3 2023 Earnings Call TranscriptSeeking Alpha • 11/14/23
OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual EventBusiness Wire • 11/09/23